{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:58:57Z","timestamp":1791935937726,"version":"4.3.4"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmedsci.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.amjms.2023.12.001","type":"journal-article","created":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T08:38:16Z","timestamp":1702111096000},"page":"155-159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Anti-ischemic and pleiotropic effects of ranolazine in chronic coronary syndromes"],"prefix":"10.1016","volume":"367","author":[{"given":"Athanasios","family":"Manolis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manolis","family":"Kallistratos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonidas","family":"Poulimenos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costas","family":"Thomopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjms.2023.12.001_bib0001","doi-asserted-by":"crossref","first-page":"298sss2","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjms.2023.12.001_bib0002","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ijcard.2016.06.150","article-title":"Medical treatment of stable angina: a tailored therapeutic approach","volume":"220","author":"Manolis","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjms.2023.12.001_bib0003","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejim.2019.09.013","article-title":"Impact of stable angina on health status and quality of life perception of currently treated patients. The BRIDGE 2 survey","volume":"70","author":"Manolis","year":"2019","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.amjms.2023.12.001_bib0004","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","article-title":"American heart association statistics committee and stroke statistics subcommittee. Heart disease and stroke statistics-2017 update: a report from the American heart association","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.amjms.2023.12.001_bib0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ejim.2019.12.012","article-title":"The ESC 2019 CCS guidelines: have we left our patients and scientific evidence behind?","volume":"72","author":"Manolis","year":"2020","journal-title":"Eur J Intern Med"},{"issue":"3","key":"10.1016\/j.amjms.2023.12.001_bib0006","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"ESC scientific document group. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.amjms.2023.12.001_bib0007","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40265-012-0005-z","article-title":"Ranolazine: a review of its use as add-on therapy in patients with chronic stable angina pectoris","volume":"73","author":"Keating","year":"2013","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.amjms.2023.12.001_bib0008","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s00392-007-0612-y","article-title":"Mechanism of action of the new antiischemia drug ranolazine","volume":"97","author":"Hasenfuss","year":"2008","journal-title":"Clin Res Cardiol"},{"issue":"Suppl. 4","key":"10.1016\/j.amjms.2023.12.001_bib0009","article-title":"Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine","volume":"92","author":"Belardinelli","year":"2006","journal-title":"Heart"},{"issue":"4","key":"10.1016\/j.amjms.2023.12.001_bib0010","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/FJC.0b013e3181a1b9e7","article-title":"A novel mechanism for the treatment of angina, arrhythmias, and diastolic dysfunction: inhibition of late INa using ranolazine","volume":"54","author":"Maier","year":"2009","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"10.1016\/j.amjms.2023.12.001_bib0011","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.pharmthera.2011.11.003","article-title":"Role of ranolazine in angina, heart failure, arrhythmias, and diabetes","volume":"133","author":"Sossalla","year":"2012","journal-title":"Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.amjms.2023.12.001_bib0012","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000362381","article-title":"The J-curve in arterial hypertension: fact or fallacy?","volume":"129","author":"Tsika","year":"2014","journal-title":"Cardiology"},{"issue":"1","key":"10.1016\/j.amjms.2023.12.001_bib0013","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1124\/jpet.110.176396","article-title":"Ranolazine increases b-cell survival and improves glucose homeostasis in low-dose streptozotocininduced diabetes in mice","volume":"337","author":"Ning","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"10.1016\/j.amjms.2023.12.001_bib0014","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.2337\/db13-1562","article-title":"Blockade of Na+ channels in pancreatic \u03b1-cells has antidiabetic effects","volume":"63","author":"Dhalla","year":"2014","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.amjms.2023.12.001_bib0015","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.hrthm.2011.03.045","article-title":"Electrophysiologic basis for the antiarrhythmic actions of ranolazine","volume":"8","author":"Antzelevitch","year":"2011","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.amjms.2023.12.001_bib0016","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jacc.2003.11.045","article-title":"Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina","volume":"43","author":"Chaitman","year":"2004","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.amjms.2023.12.001_bib0017","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.291.3.309","article-title":"Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial","volume":"291","author":"Chaitman","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.amjms.2023.12.001_bib0018","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jacc.2006.05.044","article-title":"ERICA investigators. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial","volume":"48","author":"Stone","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjms.2023.12.001_bib0019","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.jacc.2013.02.011","article-title":"Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 diabetes evaluation of ranolazine in subjects with chronic stable Angina)","volume":"61","author":"Kosiborod","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.amjms.2023.12.001_bib0020","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/2047487314533217","article-title":"Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: a systematic review and meta-analysis","volume":"22","author":"Belsey","year":"2015","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.amjms.2023.12.001_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4172\/2155-9880.1000412","article-title":"Application of ranozaline in stable angina pectoris therapy (ARETHA): real-world data from an observational study","volume":"6","author":"Diedrichs","year":"2015","journal-title":"J Clin Exp Cardiolog"},{"issue":"4","key":"10.1016\/j.amjms.2023.12.001_bib0022","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ijcard.2013.08.131","article-title":"Effects of ranolazine in symptomatic patients with stable coronary artery disease. A systematic review and meta-analysis","volume":"169","author":"Savarese","year":"2013","journal-title":"Int J Cardiol"},{"issue":"10014","key":"10.1016\/j.amjms.2023.12.001_bib0023","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0140-6736(15)00459-6","article-title":"Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Weisz","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.amjms.2023.12.001_bib0024","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1001\/jama.297.16.1775","article-title":"MERLIN-TIMI 36 Trial Investigators. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial","volume":"297","author":"Morrow","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.amjms.2023.12.001_bib0025","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijcard.2018.09.081","article-title":"Late sodium channel blockade improves angina and myocardial perfusion in patients with severe coronary microvascular dysfunction: women's Ischemia Syndrome evaluation-coronary vascular dysfunction ancillary study","volume":"276","author":"Rambarat","year":"2019","journal-title":"Int J Cardiol"},{"issue":"10","key":"10.1016\/j.amjms.2023.12.001_bib0026","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1016\/j.clinthera.2019.08.008","article-title":"Effects of the Antianginal Drugs Ranolazine, Nicorandil, and Ivabradine on Coronary microvascular function in patients with nonobstructive coronary artery disease: a meta-analysis of randomized controlled trials","volume":"41","author":"Zhu","year":"2019","journal-title":"Clin Ther"},{"key":"10.1016\/j.amjms.2023.12.001_bib0027","first-page":"1","article-title":"Efficacy of ranolazine for treatment of coronary microvascular dysfunction - a systematic review and meta-analysis of randomized trials","author":"Kofler","year":"2020","journal-title":"CJC Open"},{"key":"10.1016\/j.amjms.2023.12.001_bib0028","first-page":"ehv647","article-title":"A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve","author":"Bairey Merz","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjms.2023.12.001_bib0029","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/clc.22425","article-title":"Effects of ranolazine in patients with chronic angina in patients with and without percutaneous coronary intervention for acute coronary syndrome: observations from the MERLIN-TIMI 36 trial","volume":"38","author":"Gutierrez","year":"2015","journal-title":"Clin Cardiol"},{"issue":"1","key":"10.1016\/j.amjms.2023.12.001_bib0030","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/clc.22488","article-title":"Angina in coronary artery disease patients with and without diabetes: US national health and nutrition examination survey 2001-2010","volume":"39","author":"Hui","year":"2016","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.amjms.2023.12.001_bib0031","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/eurheartj\/ehi495","article-title":"Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes","volume":"27","author":"Timmis","year":"2006","journal-title":"Eur Heart J"},{"issue":"15","key":"10.1016\/j.amjms.2023.12.001_bib0032","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1161\/CIRCULATIONAHA.107.763912","article-title":"MERLIN-TIMI 36 Investigators. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial","volume":"119","author":"Morrow","year":"2009","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.amjms.2023.12.001_bib0033","doi-asserted-by":"crossref","first-page":"e779","DOI":"10.1161\/CIR.0000000000000766","volume":"141","author":"Arnold","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.amjms.2023.12.001_bib0034","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1161\/CIRCULATIONAHA.107.724880","volume":"116","author":"Scirica","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.amjms.2023.12.001_bib0035","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.hjc.2022.12.002","article-title":"Effects of ranolazine on various outcomes in patients with stable angina: an updated meta-analysis","volume":"71","author":"Manolis","year":"2023","journal-title":"Hellenic J Cardiol"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962923014453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962923014453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:43:39Z","timestamp":1757702619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962923014453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0002962923014453"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2023.12.001","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-ischemic and pleiotropic effects of ranolazine in chronic coronary syndromes","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2023.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}